BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Association of Pulmonary Advanced Practice Providers (APAPP) - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pulmapp.com
X-WR-CALDESC:Events for Association of Pulmonary Advanced Practice Providers (APAPP)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20260308T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20261101T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20270314T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20271107T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260911T090000
DTEND;TZID=America/New_York:20260911T120000
DTSTAMP:20260812T005526
CREATED:20260519T175625Z
LAST-MODIFIED:20260519T175831Z
UID:19327-1789117200-1789128000@www.pulmapp.com
SUMMARY:Be the Spark - Treating Tobacco Use in High-Risk Populations
DESCRIPTION:Be the Spark \nTreating Tobacco Use in High-Risk Populations \nAt the University of Pennsylvania \n \nThe NCI has created this opportunity to help guide providers as they implement tobacco treatment within their organizations. Help us get the word out about this unique and free resource. \nFall: Friday mornings (9:00 am-12:00 pm ET)\, September 11th\, Sept 18th\, Sept 25th\, October 16th \nWinter: Wednesday afternoons (12:00 pm-3:00 pm)\, February 3rd\, Feb 10th\, Feb 17th\, March 10th \nPROGRAM HIGHLIGHT \n\nTargeted Focus on Priority Populations\nEliminate Tobacco & Related Cancer Disparities\nExpert-Led Training on Cancer Populations\nImplementation-Model Development\n\nLearning Platforms \n\nAll training sessions will be conducted virtually via Zoom.\nAll assigned readings and course materials will be available via the Canvas Learning Management System (LMS)\nCanvas accounts will be activated one week prior to the first instructional session\n\nEmail pennstop@uphs.upenn.edu for more information. \n  \n 
URL:https://www.pulmapp.com/event/be-the-spark/
ATTACH;FMTTYPE=image/png:https://www.pulmapp.com/wp-content/uploads/2026/05/be-the-spark-upenn.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20260919T080000
DTEND;TZID=America/Denver:20260920T143000
DTSTAMP:20260812T005526
CREATED:20260713T162446Z
LAST-MODIFIED:20260713T162547Z
UID:19516-1789804800-1789914600@www.pulmapp.com
SUMMARY:APP Obesity National Summit
DESCRIPTION:Earn up to 7.75 AAPA Category 1 CME Credits or ANCC Nursing Contact Hours!\n\n\n\n\n\n\n\n\n\nSEPTEMBER 19–20  \nThe Westin Galleria Dallas \n\n\n\n\n\nDallas\, Texas  \n\nRegister Today!\n\n\n\n\n\n\n\n\nLed and Endorsed by \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe Inaugural APP Obesity National Summit is designed to address the growing public health crisis of obesity through targeted education for Advanced Practice Providers. \nGrounded in a multidisciplinary approach\, this event brings together clinicians from primary care\, gastroenterology\, hepatology\, rheumatology\, pulmonology\, metabolic medicine\, and cardiology. \n​The APP Obesity National Summit aims to fill this critical void by:  \n\n\nUnifying diverse specialties \n\n\nEmpowering APPs as leaders \n\n\nPreventing downstream complications \n\n\nProviding advanced\, evidence-based education \n\n\nAddressing comorbidity management \n\n\nEnhance patient-centered communications skills​ \n\n\nJoin us for this 1.5-day summit featuring the latest obesity research\, emerging management strategies\, and patient-centered care approaches across specialties.
URL:https://www.pulmapp.com/event/app-obesity-national-summit/
LOCATION:The Westin Galleria Dallas\, Dalles\, TX\, United States
ATTACH;FMTTYPE=image/avif:https://www.pulmapp.com/wp-content/uploads/2026/07/FMC-26-31-Prospectus-Logo.avif
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20261202T120000
DTEND;TZID=America/Denver:20261202T170000
DTSTAMP:20260812T005526
CREATED:20260811T160038Z
LAST-MODIFIED:20260811T160038Z
UID:19571-1796212800-1796230800@www.pulmapp.com
SUMMARY:2026 ILD Symposium
DESCRIPTION:An advanced CE-accredited afternoon symposium exploring the evolving treatment paradigm in interstitial lung disease\, including clinical development\, imaging\, CTD-ILD\, sarcoidosis\, and challenging ILD cases. \n\nEducational Outcome\nThis CE activity provides healthcare professionals with expert-led education on the evolving diagnosis and management of interstitial lung disease (ILD)\, including advances in screening\, treatment algorithms\, imaging\, and emerging therapies. Participants will gain practical insights into IPF\, PPF\, CTD-ILD\, sarcoidosis\, and complex ILD management strategies to support earlier recognition\, evidence-based treatment decisions\, and improved patient outcomes. \n\n\nCourse Objectives\nAfter completing this activity\, the participant should be better able to:\n\n\nDescribe the pathophysiology of interstitial lung disease and apply current screening protocols and treatment algorithms to optimize diagnosis and patient management\nEvaluate current and emerging approaches to ILD screening\, imaging\, and treatment algorithms\, as well as novel diagnostic technologies\nApply advances in ILD imaging to improve early detection\, disease monitoring\, and risk stratification across ILD subtypes\nRecognize the distinguishing clinical features and management considerations for special populations\, such as CTD-ILD and sarcoidosis\n\n\n\n\nTarget Audience\nThis activity is designed for pulmonologists\, rheumatologists\, radiologists\, cardiologists\, internists\, fellows\, advanced practice providers\, nurses\, pharmacists\, and other healthcare professionals engaged in the multidisciplinary care of patients with interstitial lung disease. \n\nFor more information and to register\, please visit https://www.ildsymposium.com/#home \n 
URL:https://www.pulmapp.com/event/2026-ild-symposium/
CATEGORIES:ILD
ATTACH;FMTTYPE=image/png:https://www.pulmapp.com/wp-content/uploads/2026/08/idl-conference-logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20261203T080000
DTEND;TZID=America/Denver:20261203T173000
DTSTAMP:20260812T005526
CREATED:20260811T163100Z
LAST-MODIFIED:20260811T163100Z
UID:19575-1796284800-1796319000@www.pulmapp.com
SUMMARY:23rd Annual Update in Pulmonary Hypertension
DESCRIPTION:This live CE-accredited activity is the only New England symposium that illustrates novel pathways implicated in the pathogenesis of pulmonary vascular disorders and provides state-of-the-art therapeutic approaches to the management of pulmonary hypertension. This education is accomplished via a combination of didactic lectures\, case-based plenary and breakout discussions that feature leading experts as presenters and panelists. All presentations will be based on current evidence-based guidelines\, research\, and patient-centered outcomes. \nEducational Outcome\nThis CE activity offers new and experienced healthcare providers state-of-the-art education\, recent data\, case discussions\, and practical guidance on the optimal screening and management of patients who have or are suspected of having pulmonary hypertension. It is expected that learners will utilize this education to make more informed treatment decisions that will measurably improve patient outcomes. \nObjectives\nAfter completing this activity\, the participant should be better able to: \n\nReview clinical trial evidence on the safety and efficacy of emerging drug treatment options for PH\, as well as novel pathways under development\nEvaluate new and existing therapeutic options for ILD-PH\, as well as strategies for earlier recognition and interventions for this patient population\nUtilize an interactive\, case-based learning approach in the discussion of managing PH patients with challenging comorbidities\, such as renal disease\, cancer\, non-methamphetamine drug-induced PH\, and others\nDevelop an evidence-based management plan for pulmonary hypertension that incorporates use of imaging modalities\, risk assessment tools\, pharmacologic strategies\, and routine follow-up to optimize outcomes\nDiscuss the use of combination therapies\, transition treatment strategies\, and add-on treatments in the management of PAH\nAssess Guideline-Directed Medical Therapy for HFpEF and HFrEF and novel pathways in development\nRecognize the complexities or treatment decisions in patients with CTD-associated PAH and differences from CTD-associated ILD-PH\nExplore how to incorporate a collaborative model between patients\, families\, and healthcare providers to optimize shared decision-making and improve outcomes
URL:https://www.pulmapp.com/event/23rd-annual-update-in-pulmonary-hypertension/
CATEGORIES:Pulmonary Hypertension
ATTACH;FMTTYPE=image/png:https://www.pulmapp.com/wp-content/uploads/2026/08/hypertension.png
END:VEVENT
END:VCALENDAR